Navigation Links
Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
Date:3/4/2010

LITTLETON, Colo., March 4 /PRNewswire-FirstCall/ -- Chay Enterprises, Inc. (OTC Bulletin Board: CHYE) is pleased to announce today that the company has merged with DMI Life Sciences, Inc to form Ampio Pharmaceuticals, Inc. Ampio Pharmaceuticals will trade on the NASDAQ BB under the symbol CHYE.  "We have asked FINRA to change our symbol," said Don Wingerter, Ampio Pharmaceuticals' CEO, "and expect to be trading under our new symbol in less than thirty days."

"Ampio Pharmaceuticals' management has extensive experience in drug discovery and development, and has created a substantial pipeline of pharmaceuticals that address significant, unmet medical needs.  These pharmaceutical developments are in the category of so-called 'Repurposed Drugs,' pharmaceuticals previously shown to be safe and effective treatments in distinct therapeutic categories," said Mr. Wingerter.  "By entering the public space we will have access to capital to advance our pipeline and a public forum to educate patients and showcase our commercialization activities."

Dr. David Bar-Or, Ampio Pharmaceuticals' founder and Chief Scientific Officer, stated, "I have been working for over 30 years on finding solutions to important diseases that can impact an aging population. My role as the Director of Trauma Research at two major Colorado Level One Trauma Centers has given me the unique opportunity to study a variety of diseases in both clinical and research settings."

Ampio Pharmaceuticals discovers and develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation and CNS disease.  The company develops Repurposed Drugs because they have strong potential to be safe and effective while their shorter development times can significantly increase near-term value.  The product pipeline includes new uses for previously approved drugs, some of which are now starting clinical trials, and new molecular entities ("NMEs"). A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize the company's product development programs.  By concentrating on development of Repurposed Drugs, approval timelines, costs and risk of clinical failure are reduced due to the fact that the Repurposed Drug has previously been found to be safe and effective, generally at higher dosage rates, in distinct therapeutic categories."

Safe Harbor Statement

Certain of the above statements contained in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those indicated in the forward-looking statements as a result of various factors.

SOURCE Ampio Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.ampiopharma.com

'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... 2017 The Institute for In Vitro Sciences ... recipient of a VITROCELL® inhalation exposure system thanks to ... The device, which is designed to replace animals in ... cells to airborne test materials in an environment that ... system for testing combustible tobacco products, as well as ...
(Date:7/5/2017)... England , July 5, 2017 Wolfmet ... perfect answer as physics and manufacturing combine to progress molecular ... thyroid, existing SPECT systems are unable to accurately quantify the ... only limited information regarding the success of this radiotherapy treatment ... ...
(Date:6/30/2017)... Md. , June 30, 2017 In ... since the start of May, at least ten diagnostic ... include private investments, public offerings and a loan facility.  ... million to almost $80 million.  Kalorama Information provides a ... of its Diagnostics Knowledge Center. ...
Breaking Medicine Technology:
(Date:7/23/2017)... ... July 23, 2017 , ... ... leading provider of education and training standards for healthcare treatment providers, offers ... Traditional Certification: the iaedp™ Core Curriculum. , Presented as either online or ...
(Date:7/23/2017)... , ... July 23, 2017 , ... ... thus improving communication, safety and patient-provider relationships. New tools are helping patients become ... of the 19th Annual Health Care’s Most Wired® survey, released today by the ...
(Date:7/22/2017)... ... July 21, 2017 , ... Reassured For Life ( http://www.reassured.ca ), is now ... owner and licensed broker Nerissa McNaughton. “I launched this firm because I know talking ... a very necessary conversation. I make it easy. As a broker I have access ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... financial consultations to communities in the greater Denver region, is announcing a charity ... with a very rare kind of epilepsy. , Until a few months ago, ...
(Date:7/21/2017)... ... 21, 2017 , ... Fresh Wave® IAQ today announced the launch of its ... and universities at the APPA 2017 Annual Conference and Exhibition in Booth ... odors without the use of harsh chemicals, Fresh Wave IAQ Smoke Away Air & ...
Breaking Medicine News(10 mins):